8-K: NovAccess Global Secures $26,500 Loan and New IP License to Advance Immunotherapy Platform

NovAccess Global Inc. has entered into a securities purchase agreement for a $26,500 loan and acquired a new intellectual property license to enhance its immunotherapy platform.

Summary

• NovAccess Global Inc. secured a $26,500 loan from AJB Capital Investments, LLC, with the funds intended for general working capital and debt repayment.
• The loan includes a 10% original issuance discount, resulting in net proceeds of $23,040, and carries a 12% annual interest rate.
• The promissory note is due on October 26, 2024, and can be prepaid without penalty.
• As a commitment fee, NovAccess issued 2.5 million unregistered common shares to AJB.
• The company also granted AJB a security interest in all of its assets, including the equity of StemVax, LLC.
• NovAccess is obligated to file a Form S-1 by July 28, 2024, to register the commitment fee shares and shares issuable upon conversion of the note.
• Additionally, NovAccess obtained an exclusive license from Cedars-Sinai Medical Center for the use of Isocitrate Dehydrogenase-1 (IDH1) as a biomarker to predict patient response to vaccine immunotherapy for brain tumors.
• The company intends to use IDH1 to identify patients most likely to benefit from its TRL-AD1 immunotherapy drug, which has received Orphan Drug designation from the FDA.

Sentiment

Score: 5

Explanation: The document presents a mixed picture. While the new IP license is a positive development, the loan terms are not particularly favorable, and the company faces significant financial and operational risks. The need for a future capital raise to repay the loan adds uncertainty.

Positives

• The $26,500 loan provides immediate working capital and funds for debt repayment.
• The ability to prepay the loan without penalty offers financial flexibility.
• The new intellectual property license for IDH1 could enhance the effectiveness of NovAccess's immunotherapy platform.
• The use of IDH1 as a biomarker may help identify patients most likely to respond to TRL-AD1, improving treatment outcomes.
• The Orphan Drug designation for TRL-AD1 provides regulatory advantages and market exclusivity.

Negatives

• The loan has a 10% original issuance discount, reducing the net proceeds to $23,040.
• The 12% interest rate on the loan is relatively high.
• The company is restricted from selling a significant portion of its assets or issuing additional debt without AJB's approval.
• Failure to comply with loan covenants could result in an 18% default interest rate and other penalties.
• The company has granted AJB a security interest in all of its assets, including the equity of StemVax, LLC.

Risks

• Failure to make required payments or comply with loan covenants could trigger an event of default, leading to higher interest rates and potential conversion of debt to equity at a discount.
• The company's ability to repay the note is contingent on a successful offering exceeding $5.0 million in connection with uplisting to a national securities exchange.
• The company is subject to restrictions on asset sales and debt issuance without AJB's approval.
• The company's reliance on a single intellectual property license for IDH1 could pose a risk if the license is challenged or terminated.
• The company's ability to successfully develop and commercialize TRL-AD1 is subject to regulatory approvals and clinical trial outcomes.

Future Outlook

NovAccess intends to leverage the new IDH1 license to predict patient response to its TRL-AD1 immunotherapy and is preparing to submit an Investigational New Drug (IND) application to the FDA for TRL-AD1. The company also expects to announce a partnership with a clinical manufacturing organization for vaccine testing and production readiness for phase I-II clinical trials of TLR-AD1.

Management Comments

• Dr. Dwain K. Irvin, CEO of NovAccess Global, stated that Dr. Wheelers research is incredibly important to the advancement of their immunotherapy platform for brain tumor treatment.
• Dr. Irvin anticipates that findings from work with IDH1 will complement NovAccess TLR-AD1 vaccine approach by allowing selection of the most suitable patients for treatment.

Industry Context

The announcement aligns with the growing interest in personalized medicine and the development of biomarkers to predict patient response to cancer therapies. The focus on glioblastoma, a highly aggressive brain cancer, addresses a significant unmet medical need. The use of immunotherapy and companion diagnostics is a key trend in the oncology field.

Comparison to Industry Standards

• The use of IDH1 as a biomarker is consistent with industry trends in personalized medicine, where biomarkers are used to predict patient response to therapies.
• The development of a companion diagnostic for TRL-AD1 is similar to strategies employed by other pharmaceutical companies to optimize the use of their drugs.
• The focus on glioblastoma is in line with the industry's efforts to address aggressive and difficult-to-treat cancers.
• The company's approach of combining dendritic cell vaccines with Toll-like receptor adjuvants is a novel approach to immunotherapy, but it is not yet clear how it compares to other immunotherapies in terms of efficacy and safety.
• The company's stated goal of achieving improved outcomes and enhanced life expectancy for those suffering from brain cancer is consistent with the goals of other companies in the oncology space.

Stakeholder Impact

• Shareholders may be concerned about the dilutive effect of the 2.5 million shares issued as a commitment fee and the potential for further dilution upon conversion of the note.
• Employees may be impacted by the company's financial situation and the restrictions on asset sales and debt issuance.
• Customers and patients may benefit from the development of new therapies and diagnostics, but the timeline for commercialization is uncertain.
• Suppliers and creditors may be affected by the company's financial obligations and the security interest granted to AJB.

Next Steps

• NovAccess will file a Form S-1 by July 28, 2024, to register the commitment fee shares and shares issuable upon conversion of the note.
• The company will assess IDH1 as a companion diagnostic to TRL-AD1.
• NovAccess will explore IDH1's potential as a prognostic indicator of patient response to currently marketed therapies and those in clinical development.
• The company will submit an Investigational New Drug (IND) application to the FDA for TLR-AD1.
• NovAccess expects to announce a partnership with a clinical manufacturing organization for vaccine testing and production readiness for phase I-II clinical trials of TLR-AD1.

Key Dates

Keywords

immunotherapy, biomarker, glioblastoma, brain tumor, TRL-AD1, IDH1, loan, securities purchase agreement, Orphan Drug designation, working capital